• Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests.
  • Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care.
  • We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company.
  • Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.

At Axis-Shield, innovation is fundamental to our business.

There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. Identifying these diseases quickly and efficiently, where possible at the point of care, can be vital in maintaining a patient's quality of life. New drug modalities are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.

We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.

The core focus of our business continues to be on innovation and the development of new markers with IP protection that will increase testing in the laboratory and point-of-care settings.

The company has successfully implemented its strategy of growth through the development and marketing of novel diagnostic tests in areas of clinical need since its inception and key products illustrating this include:

  • Homocysteine for identifying increased risk of cardiovascular and neurodegenerative diseases
  • Anti-CCP for early detection of rheumatoid arthritis
  • Active-B12 for improved detection of vitamin B12 deficiency
  • HbA1c assay (for monitoring disease control in diabetes) method adaption to fit Abbott automated systems

Further information is available in the Products section of this site

Additionally in  line with our strategy, we are working on markers in a number of different clinical areas including:

  • a novel test for enhanced and improved detection of vitamin D levels
  • Heparin Binding Protein - an exciting new marker for diagnosis of severe sepsis

Further information on these new assays is available in the Disease Areas section of the website

We have research centres in Norway and Scotland and more than 50 scientists are employed in this capacity.

We welcome discussion with organisations or individuals wishing to accelerate development, clinical evaluation and commercialisation of any novel markers with patent protection and potential clinical utility.

Please contact us for more information.

Axis-Shield at a Glance

A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.

About Us

› More about Axis-Shield

Focus on Afinion

Axis-Shield's award winning point-of-care test system is designed for maximum simplicity coupled with laboratory accuracy and reliability for a number of key markers important for improved patient management.

Play Afinion Demo

Afinion features

© Axis-Shield plc 2011. All rights reserved. Registered in Scotland No. SC145200 - Sitemap | Terms-of-Use | Accessibility | Disclaimer
Luna Place, The Technology Park, Dundee, DD2 1XA, Scotland. - E: shield@axis-shield.com
Diagnostics for the laboratory & the point of care in areas of clinical need including diabetes, cardiovascular & neurodegenerative disease, rheumatoid arthritis & infectious disease.